A work by Haselmayer et al. presented research on M2951, a new Burton’s tyrosine kinase (BTK) inhibitor, indicating its potential to treat AIDs such as RA and SLE by inhibiting immune cell activation [80]. Here, BTK is linked to systemic lupus erythematosus.